Continuing the tradition of providing you with timely market feedback, OBR and MDoutlook are pleased to share results from MDoutlook’s most recent Quick Poll. This survey was fielded among MDoutlook’s global network of 53,000 cancer physicians to gauge the clinical impact of the recent FDA decision to revoke marketing authorization of bevacizumab (Avastin®) in HER-2 negative metastatic Breast Cancer.
Quick Poll Methodology and Respondents’ Geographic Distribution
– 59% of responses were from US (39 states)
– 36% of responses from EU
– Overall respondents were from 24 different countries
– No financial compensation was provided to the participants
FDA’s Action Will Severely Limit the Usage of Bevacizumab in the Treatment of HER-2 Negative Metastatic Breast Cancer
Key Conclusions
– Expected to reduce by 2/3 in US
– Outside of US will still decrease by 1/3
Insurance / Payer Coverage of Bevacizumab for Metastatic Breast Cancer Will Have Significant Role in the Decision Making Process
Key Conclusion
– Nearly half of US oncologists rate payer coverage as an extremely important decision driver
– One in three oncologists outside the US also see as an extremely important factor
There is a High Amount of Interest in a Biomarker-Driven Trial for Bevacizumab in Metastatic Breast Cancer
Key Conclusion
Overall Conclusions
− Usage in the US will decrease by two-thirds
− Usage outside of the US will decrease by one-third
− More important in the US than in other locations but still of importance everywhere
− This is of the utmost importance to between 1/3 (Ex-US) and 1/2 (US) of oncologists
Final Thoughts
MDoutlook Quick Polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed are advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.
Submitted by Robert Stephan, PhD, Sr. Dir. Medical Services and Jan Heybroek, President, The Arcas Group
Great.. Very useful